Llwytho...
Anti-glypican-1 antibody–drug conjugate is a potential therapy against pancreatic cancer
BACKGROUND: Pancreatic cancer (PDAC) is the most lethal malignancy. New treatment options for it are urgently required. The aim was to develop an antibody–drug conjugate (ADC) targeting glypican-1 (GPC-1) as a new therapy for PDAC. METHODS: We evaluated GPC-1 expression in resected PDAC specimens an...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Br J Cancer |
|---|---|
| Prif Awduron: | , , , , , , , , , , , , , , , , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Nature Publishing Group UK
2020
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7189381/ https://ncbi.nlm.nih.gov/pubmed/32152502 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-020-0781-2 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|